Chiale et al., 2020 - Google Patents
Modified alphavirus-vesiculovirus hybrid vaccine vectors for homologous prime-boost immunotherapy of chronic hepatitis BChiale et al., 2020
View HTML- Document ID
- 8438542666461749729
- Author
- Chiale C
- Yarovinsky T
- Mason S
- Madina B
- Menon M
- Krady M
- Moshkani S
- Chattopadhyay Pal A
- Almassian B
- Rose J
- Robek M
- Nakaar V
- Publication year
- Publication venue
- Vaccines
External Links
Snippet
Virus-like vesicles (VLV) are hybrid vectors based on an evolved Semliki Forest virus (SFV) RNA replicon and the envelope glycoprotein (G) from vesicular stomatitis virus (VSV). Previously, we showed that VLV can be used to express protein antigens and generate …
- 229960005486 vaccines 0 title abstract description 33
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse Transcribing RNA Viruses
- C12N2740/00011—Reverse Transcribing RNA Viruses
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yan et al. | COVID-19 vaccines: a review of the safety and efficacy of current clinical trials | |
| Abdulla et al. | A summary of the SARS-CoV-2 vaccines and technologies available or under development | |
| Gómez et al. | Emerging SARS-CoV-2 variants and impact in global vaccination programs against SARS-CoV-2/COVID-19 | |
| Bettini et al. | SARS-CoV-2 mRNA vaccines: immunological mechanism and beyond | |
| Liu | A comparison of plasmid DNA and mRNA as vaccine technologies | |
| Chakraborty et al. | SARS-CoV-2 vaccines, vaccine development technologies, and significant efforts in vaccine development during the pandemic: the lessons learned might help to fight against the next pandemic | |
| Chavda et al. | Replicating viral vector-based vaccines for COVID-19: potential avenue in vaccination arena | |
| Bazhan et al. | In silico designed ebola virus T-cell multi-epitope DNA vaccine constructions are immunogenic in mice | |
| Boni et al. | HBV immune-therapy: from molecular mechanisms to clinical applications | |
| Garg et al. | Mix-and-match COVID-19 vaccinations (heterologous boost): a review | |
| Akache et al. | Effect of different adjuvants on the longevity and strength of humoral and cellular immune responses to the HCV envelope glycoproteins | |
| Salvato et al. | A single dose of modified vaccinia Ankara expressing Lassa virus-like particles protects mice from lethal intra-cerebral virus challenge | |
| Chandrasekar et al. | Localized and systemic immune responses against SARS-CoV-2 following mucosal immunization | |
| Campos et al. | A single and un-adjuvanted dose of a chimpanzee adenovirus-vectored vaccine against chikungunya virus fully protects mice from lethal disease | |
| Escalante et al. | A pentavalent Epstein-Barr virus-like particle vaccine elicits high titers of neutralizing antibodies against Epstein-Barr virus infection in immunized rabbits | |
| Esteban et al. | In the era of mRNA vaccines, is there any hope for HIV functional cure? | |
| Harahap-Carrillo et al. | Immunogenic subviral particles displaying domain III of dengue 2 envelope protein vectored by measles virus | |
| Borgoyakova et al. | Self-assembled particles combining SARS-CoV-2 RBD protein and RBD DNA vaccine induce synergistic enhancement of the humoral response in mice | |
| Kudlay et al. | COVID-19 vaccines: an updated overview of different platforms | |
| Moyo et al. | Tetravalent immunogen assembled from conserved regions of HIV-1 and delivered as mRNA demonstrates potent preclinical T-cell immunogenicity and breadth | |
| Chiale et al. | Modified alphavirus-vesiculovirus hybrid vaccine vectors for homologous prime-boost immunotherapy of chronic hepatitis B | |
| Pack et al. | SARS-CoV-2–specific vaccine candidates; the contribution of structural vaccinology | |
| De Pooter et al. | A Therapeutic Hepatitis B Virus DNA Vaccine Induces Specific Immune Responses in Mice and Non-Human Primates | |
| Murphy et al. | Understanding immune responses to Lassa virus infection and to its candidate vaccines | |
| Sundaram et al. | Immunogenicity of adjuvanted psoralen-inactivated SARS-CoV-2 vaccines and SARS-CoV-2 spike protein DNA vaccines in BALB/c mice |